Therefore, our findings suggest that GAS5 can be an ideal predictive biomarker for anti-PD-1/PD-L1 treatment and a novel therapeutic target for improving the efficacy of immunotherapeutic regimens in NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.